10,100 Shares in ICU Medical, Inc. (NASDAQ:ICUI) Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System purchased a new position in ICU Medical, Inc. (NASDAQ:ICUI) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 10,100 shares of the medical instruments supplier’s stock, valued at approximately $1,007,000.

Other hedge funds have also made changes to their positions in the company. Private Trust Co. NA increased its position in shares of ICU Medical by 1,428.6% during the 3rd quarter. Private Trust Co. NA now owns 321 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 300 shares during the period. SG Americas Securities LLC acquired a new position in shares of ICU Medical during the 4th quarter valued at $106,000. Knights of Columbus Asset Advisors LLC increased its position in shares of ICU Medical by 16.7% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 1,848 shares of the medical instruments supplier’s stock valued at $220,000 after purchasing an additional 264 shares during the period. Xponance Inc. increased its position in shares of ICU Medical by 17.8% during the 3rd quarter. Xponance Inc. now owns 2,902 shares of the medical instruments supplier’s stock valued at $345,000 after purchasing an additional 439 shares during the period. Finally, Dark Forest Capital Management LP acquired a new position in shares of ICU Medical during the 3rd quarter valued at $383,000. Institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, KeyCorp lifted their price target on ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average target price of $123.00.

Insider Activity

In other news, COO Christian B. Voigtlander sold 13,603 shares of ICU Medical stock in a transaction on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, COO Christian B. Voigtlander sold 13,603 shares of ICU Medical stock in a transaction on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director George A. Lopez sold 7,978 shares of ICU Medical stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $101.87, for a total value of $812,718.86. Following the transaction, the director now owns 877,343 shares in the company, valued at approximately $89,374,931.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,262 shares of company stock worth $2,545,532. 6.70% of the stock is owned by corporate insiders.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $96.72 on Thursday. The company has a quick ratio of 1.06, a current ratio of 2.53 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -78.63 and a beta of 0.69. The stock’s fifty day simple moving average is $102.12 and its 200 day simple moving average is $98.06. ICU Medical, Inc. has a 52-week low of $78.28 and a 52-week high of $212.43.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.39. The business had revenue of $587.86 million for the quarter, compared to analysts’ expectations of $564.77 million. ICU Medical had a positive return on equity of 6.35% and a negative net margin of 1.31%. As a group, sell-side analysts forecast that ICU Medical, Inc. will post 3.52 earnings per share for the current fiscal year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.